{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HIV-exposed+Uninfected",
    "query": {
      "condition": "HIV-exposed Uninfected"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T14:14:05.836Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01769469",
      "title": "Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "FTC/TDF (Truvada®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "22 Years",
        "sex": "MALE",
        "summary": "15 Years to 22 Years · Male only"
      },
      "enrollment_count": 101,
      "start_date": "2012-11",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2019-03-27",
      "last_synced_at": "2026-09-26T14:14:05.836Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01769469"
    },
    {
      "nct_id": "NCT01310023",
      "title": "Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Antiretroviral Toxicity"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Harvard School of Public Health (HSPH)",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5169,
      "start_date": "2007-03",
      "completion_date": "2025-05-31",
      "has_results": false,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-09-26T14:14:05.836Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01310023"
    },
    {
      "nct_id": "NCT05119959",
      "title": "Zambia Infant Cohort Study - Brains Optimized for Surviving and Thriving",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Child Development"
      ],
      "interventions": [
        {
          "name": "ECD intervention for CHEUs",
          "type": "OTHER"
        },
        {
          "name": "Usual care for CHEUs",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Boston University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "6 Months to 24 Months"
      },
      "enrollment_count": 469,
      "start_date": "2022-04-14",
      "completion_date": "2024-10-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-01",
      "last_synced_at": "2026-09-26T14:14:05.836Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05119959"
    },
    {
      "nct_id": "NCT02076178",
      "title": "Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "744 Tablet",
          "type": "DRUG"
        },
        {
          "name": "744 LA Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "18 Years to 65 Years · Male only"
      },
      "enrollment_count": 127,
      "start_date": "2014-03-27",
      "completion_date": "2016-02-23",
      "has_results": true,
      "last_update_posted_date": "2017-12-15",
      "last_synced_at": "2026-09-26T14:14:05.836Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Santa Fe",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02076178"
    },
    {
      "nct_id": "NCT05374525",
      "title": "A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "APRETUDE",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir OLI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 287,
      "start_date": "2022-05-18",
      "completion_date": "2024-08-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-09-26T14:14:05.836Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05374525"
    },
    {
      "nct_id": "NCT02720094",
      "title": "Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "TDF/FTC tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo for TDF/FTC tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo for cabotegravir oral tablet",
          "type": "DRUG"
        },
        {
          "name": "CAB LA",
          "type": "DRUG"
        },
        {
          "name": "Placebo for CAB LA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4570,
      "start_date": "2016-12-19",
      "completion_date": "2025-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-03-19",
      "last_synced_at": "2026-09-26T14:14:05.836Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02720094"
    },
    {
      "nct_id": "NCT00801697",
      "title": "Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DNA Vaccine placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd35",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd35 placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rAd5 placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 192,
      "start_date": "2009-02",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-09-26T14:14:05.836Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00801697"
    },
    {
      "nct_id": "NCT04132830",
      "title": "HIV Exposure in Utero and Metabolic Disease Risk in HIV-Negative Young Adults",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV-exposed Uninfected"
      ],
      "interventions": [
        {
          "name": "In Utero HIV Exposure",
          "type": "OTHER"
        },
        {
          "name": "No In Utero HIV Exposure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2019-10-01",
      "completion_date": "2024-07-26",
      "has_results": false,
      "last_update_posted_date": "2024-09-23",
      "last_synced_at": "2026-09-26T14:14:05.836Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04132830"
    }
  ]
}